Last updated: 2026-09-24 06:45:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Biomea Fusion, Inc. (BMEA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.44, with a market capitalisation of $123.22M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.87 to $2.99. This page covers its latest market performance, valuation, price trends and company information.
$123.22M | |
$1.70 | |
$43.69 | |
$0.87 | |
$1.70 | |
9.21M | |
1.45M | |
-- | |
$2.99 | |
$0.87 | |
-- | |
-- |
Biomea Fusion, Inc. (BMEA) last closed at $1.70 as of 2026-09-23 23:57:00, unchanged from the previous close of $1.70.
During the latest regular trading session, BMEA traded between $0.87 and $43.69, with a volume of 9.21M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Biomea Fusion, Inc. (BMEA) moved from $1.80 to $1.44, representing a decline of 20.28% ($0.37).
The stock traded between $1.35 and $1.93 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2.77 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 26.6%
BMEA is currently trading at $1.44, placing it 26.6% of the way from its 52-week low of $0.87 to its 52-week high of $2.99. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 37 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Biomea Fusion, Inc. (BMEA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.